Product Description
Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as an immunomodulator. Pomalidomide, as the newest immunomodulatory agent (IMiD), has shown substantial in vitro antiproliferative and proapoptotic effects. In vivo studies have suggested limited cross-resistance between lenalidomide and pomalidomide, and the response of pomalidomide in relapsed and refractory (RR) multiple myeloma (MM) patients, including those who are refractory to both lenalidomide and bortezomib, has induced notable enthusiasm. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24756804/)
Mechanisms of Action: IKZF1 Inducer,IKZF3 Inducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: Multiple Myeloma | Sarcoma | Sarcoma, Kaposi
Known Adverse Events: Back Pain | Labor Pain | Pain Unspecified | Anemia | Neutropenia | Respiratory Tract Infections | Dyspnea | Asthenia | Constipation | Diarrhea
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Kenya, Korea, Malawi, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Russia, Spain, Sweden, Switzerland, Taiwan, Turkey, Uganda, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Multiple Myeloma
Phase 2: Acquired Immunodeficiency Syndrome|Amyloidosis|Blood Protein Disorders|HIV Infections|Kidney Diseases|Medulloblastoma|Paraproteinemias|Sarcoma, Kaposi
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Isa-CAPED MM | P2 |
Recruiting |
Multiple Myeloma |
2029-12-31 |
|
| LCCC2119 | P2 |
Recruiting |
Multiple Myeloma |
2028-12-28 |
|
| IRB22-1781 | P2 |
Recruiting |
Multiple Myeloma |
2028-07-01 |
|
| TIKTAC-trial | P2 |
Active, not recruiting |
Kidney Diseases|Multiple Myeloma |
2028-04-20 |